Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.15252/emmm.202012465

http://scihub22266oqcxt.onion/10.15252/emmm.202012465
suck pdf from google scholar
32333818!7267110!32333818
unlimited free pdf from europmc32333818    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32333818      EMBO+Mol+Med 2020 ; 12 (6): e12465
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • COVID-19: lambda interferon against viral load and hyperinflammation #MMPMID32333818
  • Andreakos E; Tsiodras S
  • EMBO Mol Med 2020[Jun]; 12 (6): e12465 PMID32333818show ga
  • Coronavirus disease 2019 (COVID-19), triggered by the betacoronavirus SARS-CoV-2, has become one of the worst pandemics of our time that has already caused more than 250,000 deaths (JHU data-05/06/2020, https://coronavirus.jhu.edu/). Effective therapeutic approaches are urgently needed to reduce the spread of the virus and its death toll. Here, we assess the possibility of using interferon-lambda (IFNlambda), a third type of interferon sharing low homology with type I IFNs and IL-10, for treating COVID-19 patients. We discuss the unique role of IFNlambda in fine-tuning antiviral immunity in the respiratory tract to achieve optimal protection and minimal host damage and review early evidence that SARS-CoV-2 may impair IFNlambda induction, leading to a delayed type I IFN-dominated response that triggers hyperinflammation and severe disease. We also consider the potential windows of opportunity for therapeutic intervention with IFNlambda and potential safety considerations. We conclude that IFNlambda constitutes a promising therapeutic agent for reducing viral presence and hyperinflammation in a single shot to prevent the devastating consequences of COVID-19 such as pneumonia and acute respiratory distress syndrome (ARDS).
  • |Antiviral Agents/*therapeutic use[MESH]
  • |Betacoronavirus/isolation & purification/physiology[MESH]
  • |COVID-19[MESH]
  • |Coronavirus Infections/*drug therapy/immunology/pathology/virology[MESH]
  • |Cytokines/metabolism[MESH]
  • |Humans[MESH]
  • |Inflammation/etiology[MESH]
  • |Interferons/*therapeutic use[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*drug therapy/immunology/pathology/virology[MESH]
  • |SARS-CoV-2[MESH]
  • |Severity of Illness Index[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box